Higher radiation doses to the left atrium, superior vena cava, and right ventricle during SBRT for lung tumors were independently associated with worse overall survival (P=0.05).
Cohort
Does higher radiation dose to cardiac substructures reduce overall survival in patients undergoing SBRT for central and ultracentral lung tumors?
Higher radiation doses to specific cardiac substructures during SBRT for lung tumors are associated with worse overall survival, highlighting the need for substructure-specific dose constraints.
p-value: p== .05
Purpose: This study investigates the association between radiation dose to the heart base and other cardiac substructures and overall survival (OS) following stereotactic body radiation therapy (SBRT) for central and ultracentral lung tumors. Methods and Materials: ) were converted to equivalent 2 Gy fractions (EQD₂, α/β = 3 Gy). Optimal dose cut-points were defined to stratify patients into high- and low-dose groups. Cox regression models, adjusted for age, sex, tumor type, and volume, assessed the association between cardiac dose and OS; additional sensitivity analyses included bronchial Dmax. Results: = .05). Conclusions: Higher radiation doses to the left atrium, superior vena cava, and right ventricle were independently associated with worse OS after SBRT for central and ultracentral lung tumors, underscoring the importance of cardiac-substructure-specific dose constraints in SBRT planning. Moreover, a clear trend toward reduced survival with higher doses to the base of the heart underscores the importance of this region as a potential target for future dose-sparing strategies.
Kalinauskaitė et al. (Wed,) conducted a cohort in Primary and metastatic central and ultracentral lung tumors. Stereotactic body radiation therapy (SBRT) vs. Low-dose radiation to cardiac substructures was evaluated on Overall survival (p== .05). Higher radiation doses to the left atrium, superior vena cava, and right ventricle during SBRT for lung tumors were independently associated with worse overall survival (P=0.05).